Reaction of the Antitumor Antibiotic CC-1065 with DNA: Structure of a DNA Adduct with DNA Sequence Specificity
- 16 November 1984
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 226 (4676), 843-844
- https://doi.org/10.1126/science.6494915
Abstract
Sequence-dependent variations in DNA revealed by x-ray crystallographic studies have suggested that certain DNA-reactive drugs may react preferentially with defined sequences in DNA. Drugs that wind around the helix and reside within one of the grooves of DNA have perhaps the greatest chance of recognizing sequence-dependent features of DNA. The antitumor antibiotic CC-1065 covalently binds through N-3 of adenine and resides within the minor groove of DNA. This drug overlaps with five base pairs for which a high sequence specificity exists.This publication has 5 references indexed in Scilit:
- CC-1065 (NSC-298223), A MOST POTENT ANTI-TUMOR AGENT - KINETICS OF INHIBITION OF GROWTH, DNA-SYNTHESIS, AND CELL-SURVIVAL1982
- MECHANISM OF INTERACTION OF CC-1065 (NSC-298223) WITH DNA1982
- The structure of CC-1065, a potent antitumor agent and its binding to DNAJournal of the American Chemical Society, 1981
- [57] Sequencing end-labeled DNA with base-specific chemical cleavagesMethods in Enzymology, 1980
- CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism.The Journal of Antibiotics, 1978